Zelquistinel
Above: Zelquistinel structure
Below: 3D representation of a zelquistinel molecule | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| Drug class | NMDA receptor positive allosteric modulator |
| Pharmacokinetic data | |
| Bioavailability | ~100% |
| Elimination half-life | 1.2–2 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C15H25N3O5 |
| Molar mass | 327.381 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Zelquistinel (GATE-251, formerly AGN-241751) is an orally active small-molecule NMDA receptor positive allosteric modulator which is under development for the treatment of major depressive disorder (MDD) by Syndeio Biosciences, and previously by Allergan.